alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER

Pursuant to

Section 906 of the Sarbanes-Oxley Act of
2002


I, John P. Saldarelli, Treasurer and Chief
Financial Officer (Principal Financial Officer) of American
Property Investors, Inc., the General Partner of American Real
Estate Partners, L.P. (the Registrant), certify that
to the best of my knowledge, based upon a review of the American
Real Estate Partners, L.P. quarterly report on Form 10-Q
for the period ended September 30, 2004 of the Registrant
(the Report):



| |                                                                                                                                                                    
| | -------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | (1) The Report fully complies with the
    requirements of Section 13(a) or 15(d) of the Securities
    Exchange Act of 1934, as amended; and                      
|
| | (2) The information contained in the Report
    fairly presents, in all material respects, the financial
    condition and results of operations of the Registrant.



| |                       
| | ----------------------
| | /s/ JOHN P. SALDARELLI
| |                       



| |                                          
| | -----------------------------------------
| | John P. Saldarelli                       
| | Treasurer and Chief Financial
    Officer
| | American Property Investors, Inc.,       
| | the General Partner of                   
| | American Real Estate Partners, L.P.      

Date: November 9, 2004
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.35 Written submissions to an advisory committee. ( a ) Ten copies of written submissions to a committee are to be sent to the Designated Federal Officer unless an applicable Federal Register notice or other regulations in this chapter specify otherwise. Submissions are subject to the provisions of § 10.20, except that it is not necessary to send copies to the Dockets Management Staff.
( b ) At the request of a committee, or on the Commissioner's own initiative, the Commissioner may issue in the Federal Register a notice requesting the submission to the committee of written information and views pertinent to a matter being reviewed by the committee. The notice may specify the manner in which the submission should be made.
( c ) At the request of a committee, or on the Commissioner's own initiative, the Commissioner may at any time request the applicant or sponsor of an application or petition about a specific product on which action is pending before FDA, and is being reviewed by an advisory committee, to present or discuss safety, effectiveness, or other data concerning the product during a regularly scheduled meeting of the committee. The request may be for an oral presentation or for a concise, well-organized written summary of pertinent information for review by the committee members before the meeting, or both. Unless specified otherwise, one copy of the written summary along with a proposed agenda outlining the topics to be covered and identifying the participating industry staff members or consultants that will present each topic is to be submitted to the Designated Federal Officer or other designated agency employee at least 3 weeks before the meeting.
( d ) An interested person may submit to a committee written information or views on any matter being reviewed. Voluminous data is to be accompanied by a summary. A submission is to be made to the Designated Federal Officer and not directly to a committee member. ( 1 ) FDA will distribute submissions to each member, either by mail or at the next meeting. Submissions will be considered by the committee in its review of the matter.
( 2 ) A committee may establish, and give public notice of, a cutoff date after which submissions about a matter will no longer be received or considered.
( e ) The Commissioner will provide the committee all information the Commissioner deems relevant. A member will, upon request, also be provided any material available to FDA which the member believes appropriate for an independent judgment on the matter, e.g., raw data underlying a summary or report, or a briefing on the legal aspects of the matter.
#### Agatha Nugent, Plaintiff-Appellant, v. City of Chicago, a Municipal Corporation, Defendant-Appellee.

Gen. No. 52,709. (Abstract of Decision.)

First District, Third Division.

May 8, 1969.

Thomas William Burke, of Chicago, for appellant;

Raymond P. Simon, Corporation Counsel of City of Chicago (Marvin E. Aspen and Stuart Sikevitz, Assistant Corporation Counsel, of counsel), for appellee.

Opinion by

PRESIDING JUSTICE SULLIVAN.

Not to be published in full.
J ~~~EO sr qT ~
s UNITED STATES ENVIRONMENTAL PROTECTION AGENCY Q WASHINGTON, D.C. 20460 z ~l~(/► ~

0 PROS

~ G

~ `

OFFICE OF AIR AND RADIATION 

## OCT ® 2 2014
Ann Lee-Jeffs Leader, Product Stewardship Honeywell International Inc. 101 Columbia Road Morristown, NJ 07962-1039 Re: Completeness Determination for SNAP Submission for Solstice ® N-13 in Refrigeration and Air Conditioning.
Dear Ms. Lee-Jeffs: Thank you for Honeywell's submission to the Environmental Protection Agency (EPA) for Solstice ® N-13 in refrigeration and air conditioning. EPA established the Significant New Alternatives Policy (SNAP) program to implement section 612 of the Clean Air Act. Your submission received on May 29, 2014 has been reviewed for completeness. We have found the information to be complete. Here is a summary of information concerning your submission: Substitute name: Solstice ® N-13 Sector: Refrigeration and Air Conditioning End uses: Retail food, refrigerated transport, vending, water coolers, cold water storage warehouses, industrial process refrigeration, chillers, domestic refrigerators, cascade refrigeration systems, industrial process air-conditioning. New or retrofit usage: Retrofits and New Equipment Date received: May 29, 2014 Date of most recent information received: September 16, 2014 Status of submission: Complete Your submission was complete as of September 16, 2014. EPA has 90 days from this date to render a decision about the acceptability of Solstice ® N-13 in the specified end-uses. You may ,

Internet Address (URL) • http //www.epa.gov RecycledlRecyclabte • Printed with Vegetable Oil Based Inks on 100% Postconsumer. Process Chlorine Free Recycled Papersell or import Solstice ® N-13 for use in the refrigeration and air conditioning end-uses described

above as of December 15, 2014. If you have questions about your submission, please me at (202) 343-9624 or Wozniak.e

g rald ~ epa.go_v . 

### Sincerely, 

# X4 , Z.." Gerald Wozniak Alternatives and Emissions Reduction Branch Stratospheric Protection Division
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
 

REGION VII
 

901 NORTH 5TH STREET 

KANSAS CITY, KANSAS 66101 

September 23, 2011 

Lawrence E Copeland Jr 

P O Box 4011 

Mcchord Afb, Washington 98438 

RE: SAID: 548 

2416 Binney Street 

Lead-Based Paint (LBP) Assessment 

Dear Owner/Resident: 

A Lead Based Paint assessment was recently performed on your property by the U.S. 

Environmental Protection Agency as part of the Omaha Lead site investigation. The purpose of 

this assessment is to determine whether a significant quantity of LBP is present on the exterior 

surface of structures, where deteriorating paint conditions (peeling, flaking, cracking, etc) exist 

that might increase lead concentrations in the yard above acceptable levels. 

Enclosed are the LBP assessment sheets for 2416 Binney Street. The EPA has developed paint 

stabilization eligibility criteria that involve measuring the amount of deteriorated LBP on a 

structure and calculating the concentration of lead in soils around the home that would result if 

all of the identified deteriorated paint were to fall to the ground and uniformly mix with the soil 

under certain assumptions. During the LBP assessment, the areal extent of the deteriorated paint 

observed on structure surfaces was estimated and the lead content in the deteriorated paint was 

measured using an X-Ray Fluorescence instrument. 

The data obtained during the LBP assessment was used to estimate the increase in soil lead 

concentration that would result if all of the deteriorating paint identified in the assessment were 

to fall to the ground and mix with surface soil within six feet of the foundation of the structure. 

For purposes of this calculation, the deteriorating LBP on a structure is assumed to fall onto the 

ground surface within six feet of the foundation and be uniformly mixed with the top one inch 

of soil. The estimated lead concentration in the soil potentially caused by the deteriorating LBP 

provides a measure of the severity of LBP deterioration on individual structures. The EPA uses 

these criteria to rank properties based on the potential for recontamination of soil to occur. Paint 

stabilization is being offered at only those households with the most severe LBP problems, 

particularly where children under the age of seven reside. 

The LBP assessment performed by the EPA using the above criteria indicated that your 

house IS NOT eligible for paint stabilization. 
 

 

 

If you have any questions or concerns, please contact the EPA Public Information Center at 

(402) 731-3045. 

Sincerely, 

Pauletta R. France-Isetts 

Project Coordinator 

Environmental Protection Agency 

Enclosures 

Para información en español, llame al EPA Information Center (402) 731-3045. 

- - - - -- 

Omaha Lead Site ~orthArrow 

Address:2416 BINNEY ST Site Sketch 

LBP Assessment 

ALT 1 

Plan View - Indicate number of stories and perimeter dimensions of structure 


Indicate regions of deterioration and describe 


(Deterlorat~an could include surfaces that are worn due to fridon checkmg, crackmg and flakmg all~gatormg, bl~stenng andior peelmg) 


Phone:-"-
<PAGE>   1
                                                                    EXHIBIT 23.1


                         CONSENT OF INDEPENDENT AUDITORS
--------------------------------------------------------------------------------


The Board of Directors
INTERLINQ Software Corporation:

We consent to the incorporation by reference in the registration statements
(Nos. 33-63388, 333-4558 and 333-21099) on Form S-8 of INTERLINQ Software
Corporation of our report dated June 30, 1998, relating to the balance sheets of
INTERLINQ Software Corporation as of June 30, 1998 and 1997, and the related
statements of operations, shareholders' equity, and cash flows for each of the
years in the three-year period ended June 30, 1998, and the related schedule,
which report appears in the June 30, 1998, annual report on Form 10-K of
INTERLINQ Software Corporation.


/s/ KPMG Peat Marwick LLP

Seattle, Washington
September 25, 1998


                                       51
IV 

115TH CONGRESS 

2D SESSION H. RES. 1003 

Prohibiting Members of the House of Representatives from soliciting 

campaign funds on any day on which the House is in session. 

IN THE HOUSE OF REPRESENTATIVES 

JULY 18, 2018 

Mr. NOLAN (for himself and Mr. GALLAGHER) submitted the following 

resolution; which was referred to the Committee on Ethics 

RESOLUTION 

Prohibiting Members of the House of Representatives from 

soliciting campaign funds on any day on which the House 

is in session. 

1 Resolved, 

2 SECTION 1. PROHIBITING MEMBERS FROM SOLICITING 

3 CAMPAIGN FUNDS WHEN HOUSE IS IN SES4 SION. 

5 Rule XXIII of the Rules of the House of Representa6 tives, as amended by section 6 of House Resolution 724, 

7 One Hundred Fifteenth Congress, is amended— 

8 (1) by redesignating clause 19 as clause 20; 

9 and 


lotter on DSKBCFDHB2PROD with BILLS
2 

•HRES 1003 IH 

1 (2) by inserting after clause 18 the following 

2 new clause: 

3 ‘‘19. On any day on which the House is in session 

4 (other than a day on which the House convenes solely in 

5 a pro forma session), a Member, Delegate, or Resident 

6 Commissioner may not solicit any funds in connection with 

7 an election for Federal office or an election for State or 

8 local office.’’. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS
EXHIBIT 23.1

               CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

As independent certified public accountants, we hereby consent to the
incorporation by reference of our report dated January 26, 2001 on the
consolidated financial statements of SportsLine.com, Inc. and subsidiaries into
the Company's previously filed registration statements on Form S-3 (Registration
Nos. 333-39618, 333-62685 and 333-78921) and Form S-8 (Registration Nos.
333-43746, 333-46021, 333-46023, 333-46029 and 333-57821, 333-33650 and
333-33654).


Arthur Andersen LLP

Fort Lauderdale, Florida,
  March 28, 2001.
§ 225.30 Equipment. ( a ) Equipment which is designed to perform its intended function and is properly installed and used is essential to the manufacture of medicated feeds. Such equipment permits production of feeds of uniform quality, facilitates cleaning, and minimizes spillage of drug components and finished product.
( b ) ( 1 ) All equipment shall possess the capability to produce a medicated feed of intended potency, safety, and purity.
( 2 ) All equipment shall be maintained in a reasonably clean and orderly manner.
( 3 ) All equipment, including scales and liquid metering devices, shall be of suitable size, design, construction, precision, and accuracy for its intended purpose.
( 4 ) All scales and metering devices shall be tested for accuracy upon installation and at least once a year thereafter, or more frequently as may be necessary to insure their accuracy.
( 5 ) All equipment shall be so constructed and maintained as to prevent lubricants and coolants from becoming unsafe additives in feed components or medicated feed.
( 6 ) All equipment shall be designed, constructed, installed and maintained so as to facilitate inspection and use of cleanout procedure(s).
§ 139.138 Whole wheat macaroni products. ( a ) Whole wheat macaroni products are the class of food each of which conforms to the definition and standard of identity and is subject to the requirements for label statement of ingredients, prescribed for macaroni products by § 139.110(a), (f)(2), (f)(3), and (g), except that: ( 1 ) Whole wheat flour or whole durum wheat flour or both are used as the sole wheat ingredient; and
( 2 ) None of the optional ingredients permitted by § 139.110(a) (1), (2), and (5) is used.
( b ) Whole wheat macaroni is the whole wheat macaroni product the units of which conform to the specifications of shape and size prescribed for macaroni by § 139.110(b).
( c ) Whole wheat spaghetti is the whole wheat macaroni product the units of which conform to the specifications of shape and size prescribed for spaghetti by § 139.110(c).
( d ) Whole wheat vermicelli is the whole wheat macaroni product the units of which conform to the specifications of shape and size prescribed for vermicelli by § 139.110(d).
( e ) The name of each food for which a definition and standard of identity is prescribed by this section is “Whole wheat macaroni product”; or alternatively, the name is “Whole wheat macaroni”, “Whole wheat spaghetti”, or “Whole wheat vermicelli”, as the case may be, when the units of the food comply with the requirements of paragraph (b), (c), or (d), respectively, of this section.
[42 FR 14409, Mar. 15, 1977, as amended at 58 FR 2878, Jan. 6, 1993]
<PAGE>   1
                                  EXHIBIT 24.3

                                POWER OF ATTORNEY
                               LUCIE J. FJELDSTAD

     KNOW ALL MEN BY THESE PRESENTS, that the undersigned, Lucie J. Fjeldstad,
hereby constitutes and appoints Gordon A. Gardiner or Peter A. Allen her true
and lawful attorney-in-fact and agent, for her and her name, place and stead, in
any and all capacities, to sign the Form 10-K of Data Dimensions, Inc., a
Delaware corporation, for the fiscal year ended December 31, 1998, and any
amendments or supplements thereto, and to file this Power of Attorney and the
Form 10-K, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission and the NASDAQ National
Market System, granting unto said attorney-in-fact and agent full power and
authority to do and perform each requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as she might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact and
agent, may do or cause to be done by virtue hereof.


     Dated this 4th day of March, 1999.


Signature:


/s/  LUCIE J.  FJELDSTAD
----------------------------
Lucie J. Fjeldstad
§ 20.90 Disclosure to contractors. ( a ) Data and information otherwise exempt from public disclosure may be disclosed to contractors with the Food and Drug Administration and their employees for use only in their work for the Food and Drug Administration. Contractors and their employees are thereafter subject to the same legal restrictions and penalties with respect to the disclosure of such data and information as Food and Drug Administration employees.
( b ) A written agreement between the Food and Drug Administration and any contractor shall be entered into before data and information otherwise exempt from public disclosure may be disclosed to the contractor. The contractor shall agree to establish and follow security precautions considered by the Food and Drug Administration to be necessary to ensure proper and confidential handling of the data and information. The written agreement shall include, where appropriate, provisions establishing: ( 1 ) Restrictions on access to the data and information by the contractor, its employees, or other persons;
( 2 ) Physical storage requirements;
( 3 ) Requirements for the handling and accountability of the data and information by the contractor and its employees;
( 4 ) Limitations on reproduction, transmission, and disclosure of the data and information;
( 5 ) A requirement of advance approval by the Food and Drug Administration of the use by the contractor of subcontractors, vendors, or suppliers;
( 6 ) Procedures to be followed when the contractor employs time-shared computer operations;
( 7 ) Methods of destroying source documents or related waste material; and
( 8 ) The period during which the contractor may retain such data and information.
§ 520.2345h Tetracycline hydrochloride, sodium novobiocin, and prednisolone tablets. ( a ) *Specifications.* Each tablet contains the equivalent of 60 milligrams of tetracycline hydrochloride, 60 milligrams of novobiocin, and 1.5 milligrams of prednisolone or 180 milligrams of tetracycline hydrochloride, 180 milligrams of novobiocin, and 4.5 milligrams of prednisolone.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 10 milligrams of each antibiotic and 0.25 milligram of prednisolone per pound of body weight (one single-strength tablet for each 6 pounds or one triple-strength tablet for each 18 pounds) every 12 hours for 48 hours. Treatment is to be continued with novobiocin and tetracycline alone at the same dose schedule for an additional 3 days or longer as needed.
( 2 ) *Indications for use.* Treatment of acute and chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as *Staphylococcus* spp. and *Escherichia coli,* when it is necessary to initially reduce the severity of associated clinical signs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37329, Aug. 18, 1992, as amended at 79 FR 28832, May 20, 2014]
<PAGE>   1
                                                                   EXHIBIT 12.1


                    DEFICIENCY OF EARNINGS TO FIXED CHARGES

        The deficiency of earnings to fixed charges for each of the years in
the five-year period ended December 31, 1996 and for the nine-month periods
ended September 30, 1997 and 1996 is presented below. Ratio of earnings to
fixed charges means the ratio of pretax income from continuing operations (with
certain adjustments described below) to the total of: (i) interest and (ii)
such portion of rental expense as can be demonstrated to be representative of
the interest factor in the particular case.

<TABLE>
<CAPTION>
                                                        Nine Months Ended 
                                                           September 30,                   Year Ended December 31,    
                                                        ------------------    -------------------------------------------------
                                                          1997      1996        1996      1995        1994     1993     1992 
                                                        ------------------    ------------------------------------------------- 
                                                                           (dollars in thousands)
<S>                                                     <C>        <C>        <C>        <C>        <C>       <C>       <C> 
Historical:

EARNINGS BEFORE FIXED CHARGES:

Net (Loss)                                              $(3,962)   $(2,526)   $(4,229)   $(3,758)   $ (385)   $ (761)   $2,023)

Add: Interest Expense                                   $ 7,378    $ 5,884    $ 8,263    $ 7,215    $ 3,226   $ 2,592   $ 3,051
     Interest factor in rental expense                  $   142    $   124    $   145    $   143    $    71   $    63   $    61

EARNINGS BEFORE FIXED CHARGES                           $ 3,558    $ 3,482    $ 4,179    $ 3,600    $ 2,912   $ 1,894   $ 1,089

FIXED CHARGES:
     Interest Expense                                   $ 7,378    $ 5,884    $ 8,263    $ 7,215    $ 3,226   $ 2,592   $ 3,051
     Interest factor in rental expense                  $   142    $   124    $   145    $   143    $    71   $    63   $    61 

TOTAL FIXED CHARGES                                     $ 7,520    $ 6,008    $ 8,408    $ 7,358    $ 3,297   $ 2,655   $ 3,112 

RATIO OF EARNINGS TO FIXED
  CHARGES                                                     -          -          -          -          -         -         -

DEFICIENCY IN EARNINGS AVAILABLE TO 
  COVER FIXED CHARGES                                   $(3,962)   $(2,526)   $(4,229)   $(3,758)   $  (385)  $  (761)  $(2,023)
</TABLE>